Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) Antibodies:
anti-Mouse (Murine) Antibodies:
Go to our pre-filtered search.
Cow (Bovine) Monoclonal PPARA Primary Antibody for ChIP, FACS - ABIN152696
Sumanasekera, Tien, Turpey, Vanden Heuvel, Perdew: Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2. in The Journal of biological chemistry 2003
Show all 9 Pubmed References
Cow (Bovine) Polyclonal PPARA Primary Antibody for ChIP, ELISA - ABIN153509
Selwyn, Cheng, Klaassen, Cui: Regulation of Hepatic Drug-Metabolizing Enzymes in Germ-Free Mice by Conventionalization and Probiotics. in Drug metabolism and disposition: the biological fate of chemicals 2016
Show all 6 Pubmed References
Human Monoclonal PPARA Primary Antibody for WB - ABIN1944858
Mukherjee, Jow, Noonan, McDonnell: Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. in The Journal of steroid biochemistry and molecular biology 1995
Show all 4 Pubmed References
Human Polyclonal PPARA Primary Antibody for ICC, IHC (fro) - ABIN3044397
Zhou, Zhang, Xu, Wang: Curcumin ameliorates renal fibrosis by inhibiting local fibroblast proliferation and extracellular matrix deposition. in Journal of pharmacological sciences 2015
Show all 3 Pubmed References
Mouse (Murine) Polyclonal PPARA Primary Antibody for IF, IP - ABIN285918
Suardíaz, Estivill-Torrús, Goicoechea, Bilbao, Rodríguez de Fonseca: Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. in Pain 2007
Show all 2 Pubmed References
Mouse (Murine) Polyclonal PPARA Primary Antibody for IHC, ELISA - ABIN105798
Plutzky: Medicine. PPARs as therapeutic targets: reverse cardiology? in Science (New York, N.Y.) 2003
Show all 2 Pubmed References
Human Polyclonal PPARA Primary Antibody for IF (p), IHC (p) - ABIN753163
Mölzer, Wallner, Kern, Tosevska, Schwarz, Zadnikar, Doberer, Marculescu, Wagner: Features of an altered AMPK metabolic pathway in Gilbert's Syndrome, and its role in metabolic health. in Scientific reports 2016
Mouse (Murine) Monoclonal PPARA Primary Antibody for GS, IP - ABIN284693
Longuet, Sinclair, Maida, Baggio, Maziarz, Charron, Drucker: The glucagon receptor is required for the adaptive metabolic response to fasting. in Cell metabolism 2008
Cow (Bovine) Polyclonal PPARA Primary Antibody for IHC, WB - ABIN2778248
Gu, Yang, Lin, Li, Li, Zhong, Peng, Cui: Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting. in Hepatology (Baltimore, Md.) 2014
Data suggest that, in hepatocytes, MIRN34A plays roles in regulation of mitochondrial remodeling and lipid metabolism including development/prevention of non-alcoholic fatty liver disease; MIRN34A appears to act via AMPK (show PRKAA1 Antibodies)/PPARalpha signal transduction. (MIRN34A = microRNA 34a; AMPK (show PRKAA1 Antibodies) = AMP-activated protein kinase (show PRKAA2 Antibodies); PPARalpha = peroxisome proliferator activated receptor alpha)
miR (show MLXIP Antibodies)-214 overexpression inhibits glioma cell growth in vitro and in vivo by inducing cell cycle arrest in G0/G1. Collectively, these data uncover a novel role for a PPARalpha-miR (show MLXIP Antibodies)-214-E2F2 (show E2F2 Antibodies) pathway in controlling glioma cell proliferation.
Improvements in metabolic and neurodegenerative diseases are often attributed to anti-inflammatory effects of PPAR activation. (Review)
circRNA_0046366, which demonstrated expression loss in HepG2-based hepatocellular steatosis, exerts antagonistic effect on miR (show MLXIP Antibodies)-34a activity. miR (show MLXIP Antibodies)-34a inactivation abrogates its inhibitory role against PPARalpha.
We first reported that the FOMX1 pathway is the most upregulated and the PPARalpha pathway is the most downregulated pathway in Triple Negative Breast Cancers (TNBCs). These two pathways could be simultaneously targeted in further studies. Also the pathway classifier we performed in this study provided insight into the TNBC heterogeneity.
Polymorphism of PPARA is associated with late onset of type 2 diabetes mellitus.
results demonstrated that OEA exerts anti-inflammatory effects by enhancing PPARalpha signaling, inhibiting the TLR4 (show TLR4 Antibodies)-mediated NF-kappaB (show NFKB1 Antibodies) signaling pathway, and interfering with the ERK1/2-dependent signaling cascade (TLR4 (show TLR4 Antibodies)/ERK1/2/AP-1 (show FOSB Antibodies)/STAT3 (show STAT3 Antibodies)), which suggests that OEA may be a therapeutic agent for inflammatory diseases.
data suggested that miR (show MLXIP Antibodies)-19a negatively controlled the autophagy of hepatocytes attenuated in D-GalN (show GAL Antibodies)/LPS (show IRF6 Antibodies)-stimulated hepatocytes via regulating NBR2 and AMPK (show PRKAA1 Antibodies)/PPARalpha signaling.
The minor allele of rs1800206 and rs1805192 from PPAR A and PPAR G (show ARF6 Antibodies) and its interaction were associated with increased Breast Cancer risk.
High concentrations of DINCH urinary metabolites activate human PPAR-alpha.
This study investigated FA composition in yaks and cattle, in order to ascertain whether a correlation between PPARalpha signal pathway genes as candidate genes and meat FA composition in yaks and cattle exists.
OCTN2 (show SLC22A5 Antibodies) expression and carnitine transport in cattle, as in rodents, are regulated by PPARalpha.
In conclusion, H8H8 haplotype combination of the PPARalpha may be advantageous for heat resistance traits in Chinese Holstein cattle.
Data suggest that PPARalpha (but not PPARgamma (show PPARG Antibodies)) is involved in vasorelaxation of ophthalmic artery in response to endocannabinoids (i.e., anandamide, palmitoylethanolamide); endothelium removal slightly decreases the response to endocannabinoids.
Data from gene profiling experiments in bovine cell line support hypothesis that saturated long-chain fatty acids modulate ruminant lipid metabolism and expression of inflammation mediators with major effects induced via activation of PPARalpha.
Dietary trans fatty acids may affect liver lipid metabolism in post-partum dairy cows through alterations in PPARalpha gene expression.
Oxidized fataprevent an alcohol-induced triacylglycerol accumulation in rats possibly by upregulation of hepatic PPARalpha-responsive genes, whwereas conjugated linoleic acid does not.
The results are consistent with the hypothesis that arachidonic acid acts via PPARalpha to increase PTGS2 (show PTGS2 Antibodies) levels in bovine endometrial stromal cells.
Our results provide novel insights into regulation of PPAR expression in ovarian follicles. We observed that FSH (show BRD2 Antibodies) increased mRNA and protein expression of all PPARs isoforms, while LH only increased PPAR alpha and gamma. Steroids like progesterone and estradiol increased expression of PPAR alpha and gamma without affecting the beta isoform, while testosterone had no effect on all PPARs expression.
The c.*636A>G SNP in the PPARA gene can be considered in Polish Landrace breed as a useful genetic marker for adipose tissue accumulation.
The results indicate that the endometrial expression of PPARalpha genes fluctuates during the estrous cycle and pregnancy.
PPARalpha is likely to play a central role in adaptation to fasting in pig liver
Despite expression of PPAR-alpha in porcine myocardium and effects of fenofibrate on systemic metabolism, treatment with this PPAR-alpha activator does not alter myocardial metabolic or contractile responses to I/R in pigs.
FISH localization of 4 BAC clones harbouring potential candidate genes for fatness traits: DGAT1 (show DGAT1 Antibodies) (SSC4p15), PPARA (SSC5p15), ADIPOR1 (show ADIPOR1 Antibodies) (SSC10p13) and CREB (show CREB1 Antibodies) (SSC15q24)
PPAR profiles in bladder smooth muscle (BSM (show MUC19 Antibodies)) may contribute to the susceptibility of BSM (show MUC19 Antibodies) to lipotoxicity in the metabolic syndrome.
These data may indicate that insulin (show INS Antibodies) resistance in Adp(-/-) mice is likely caused by an increase in concentrations of TNFalpha (show TNF Antibodies) and FFA via downregulation of PPARalpha.
Results from transcriptional and epigenomic analyses in the livers of mice fed either a high-fat diet or nutrition-restricted diet, found extensive binding of PPARalpha near genes involved in glycolysis/gluconeogenesis and uncovered a role for this factor in regulating anaerobic glycolysis.
Peroxisome proliferator-activated receptor alpha (PPARalpha) target gene expression was almost absent in contrast to increased lipid synthesis in the TIS21 (show BTG2 Antibodies) protein (TIS21 (show BTG2 Antibodies)) knockout (TIS21 (show BTG2 Antibodies)-KO) mice compared to WT mice.
Clofibrate treatment revealed an essential role of PPARalpha in regulating hepatic bile acid synthesis, transport and signaling.
IL-6 and aging are involved in regulation of PPARalpha and PGC-1alpha expression and may influence the mitochondrial function.
The authors identify an endogenous role for PPARalpha in retinal neuronal survival and lipid metabolism, and furthermore underscore the importance of fatty acid oxidation in photoreceptor survival. They also suggest PPARalpha as a putative therapeutic target for age-related macular degeneration, which may be due in part to decreased mitochondrial efficiency and subsequent energetic deficits
p21 (show D4S234E Antibodies) plays a relevant role in fasting adaptation through the positive regulation of PPARalpha.
PPARalpha is required for the ChREBP (show MLXIPL Antibodies)-induced glucose response of FGF21 (show FGF21 Antibodies). Loss of PPARalpha impairs Fgf21 (show FGF21 Antibodies) promoter accessibility at the carbohydrate-responsive element .
Data, including data from studies in knockout mice, suggest that hepatic induction of cytochrome P450s (Cyp3a, Cyp2b, and Cyp2c) by hypolipidemic agent gemfibrozil is suppressed by Ppara activation.
We demonstrated that PPARalpha activation contributes to liver protection and decreases liver inflammation in acute liver failue (ALF (show GTF2A1L Antibodies)), particularly through regulating CHOP (show DDIT3 Antibodies). Our findings may provide a rationale for targeting PPARalpha as a potential therapeutic strategy to ameliorate ALF (show GTF2A1L Antibodies).
Peroxisome proliferators include hypolipidemic drugs, herbicides, leukotriene antagonists, and plasticizers\; this term arises because they induce an increase in the size and number of peroxisomes. Peroxisomes are subcellular organelles found in plants and animals that contain enzymes for respiration and for cholesterol and lipid metabolism. The action of peroxisome proliferators is thought to be mediated via specific receptors, called PPARs, which belong to the steroid hormone receptor superfamily. PPARs affect the expression of target genes involved in cell proliferation, cell differentiation and in immune and inflammation responses. Three closely related subtypes (alpha, beta/delta, and gamma) have been identified. This gene encodes the subtype PPAR-alpha, which is a nuclear transcription factor. Multiple alternatively spliced transcript variants have been described for this gene, although the full-length nature of only two has been determined.
, nuclear receptor subfamily 1 group C member 1
, peroxisome proliferative activated receptor, alpha
, peroxisome proliferator-activated nuclear receptor alpha variant 3
, PPAR alpha
, peroxisome proliferator activated receptor alpha
, peroxisome proliferator-activated receptor alpha
, ppar alpha
, xPPAR alpha
, peroxisome proliferator-activated receptor-alpha